Fimvo Strategy 2026-2028







Fimvo as an organisation

- Fimvo was established in 2016 to implement the medicines verification system required by the EU Falsified Medicines Directive (2011/62/EU) and its Delegated Regulation ((EU) 2016/161).
- We are a non-profit limited company founded and owned by Pharma Industry Finland, Orion Corporation, the Finnish Generic Pharmaceutical Association, Suppliers of Parallel Imported Medicines in Finland, the Association of Finnish Pharmacies and the Association of Pharmaceutical Distributors.







Fimvo's duties

- Fimvo maintains and develops the Finnish medicines verification system, which
 prevents falsified medicines from entering the legal supply chain.
- Through this system, we strengthen patients' trust in a safe pharmaceutical distribution chain and the availability of genuine medicines.
- Finnish pharmacies, hospital pharmacies, dispensaries, and pharmaceutical wholesalers are connected to the medicines verification system.
- Marketing authorisation holders upload the unique identifiers of prescription medicine packs into the system via the European central database, the EU Hub.
- We support users of the medicines verification system in fulfilling their legal obligations by providing guidance and training.
- We do not have any licensing or supervisory authority.








Fimvo is part of the European medicines verification system

- The Finnish medicines verification system is part of a European network that includes all EU and EEA countries.
- Each country has its own national medicines verification system, all of which are interconnected through a central database known as the EU Hub. This hub is managed by the European Medicines Verification Organisation (EMVO).



European Medicines Verification System (EMVS)





Manufacturer: data upload + voluntary verification



Parallel Distributor: mandatory verification + data upload



Periodic crossregion update



Pharmacy: mandatory verification



Wholesaler: voluntary verification



Fimvo's operational environment

- We operate in a highly regulated environment under the supervision of Fimea, the Finnish Medicines Agency.
- We manage a high-technology IT system and must continuously stay at the forefront of technological development.
- Our operations take place in an international context, where pharmaceutical supply chain stakeholders hold differing views on the use of the medicines verification system, both nationally and at the European level.





Fimvo's SWOT analysis

STRENGTHS

- Strong legislative foundation
- High-technology system and EU integration
- Key role in ensuring a secure distribution chain

3

- Small organisational size limited resources for development
- Dependence on external IT partners

WEAKNESSES

Divergent views on the development of the medicines verification system

OPPORTUNITIES

- Utilising digitalisation and artificial intelligence
- Deepening cooperation at EU level
- Using data to enhance medication safety
- Expanding into other areas of medication safety

THREATS

- Cybersecurity threats and data breaches
- Legislative changes
- Rapid technological development and evolving system requirements
- Increasing sophistication of medicine falsifiers




Fimvo's vision and mission

VISION

A safe and sustainable supply chain in which patients can trust the authenticity of their prescription medicines.

MISSION

We manage and develop the medicines verification system to ensure the authenticity of patients' prescription medicines and to leverage our potential to enhance the safety and sustainability of the pharmaceutical supply chain.







Our values

EXPERTISE

We focus on solutions and see things through to completion. We work for the benefit of Finnish patients.

RESPONSIBILITY

We act ethically and treat all actors in the pharmaceutical supply chain fairly.
We provide safety and assurance for Finnish patients.

PROACTIVITY

We act proactively and inclusively.


POSITIVITY

We value one another and take joy and pride in our work.





Fimvo's strategic pillars





Patient safety

 We enhance citizens' overall safety by being an essential part of a secure pharmaceutical supply chain. Through our operations, we safeguard the continuity of medicine supply and strengthen public trust in genuine medicines.

 With our medicines verification system, we prevent falsified medicines from entering legal distribution channels. Pharmacies and other supply chain actors verify the information on medicine packs in the system before dispensing them to patients.

 In cooperation with supply chain stakeholders, the medicines verification system helps prevent incorrect or expired medicines from reaching patients. The system supports safe medication practices and reduces the risk of medication errors.



LEADERSHIP

PATIENT

SAFETY

COLLABORATION

Collaboration

 We continue our close cooperation with stakeholders across the pharmaceutical supply chain. We provide support to users of the medicines verification system to help them effectively meet the legal requirements related to medicines verification.

 We assist Fimea in investigating cases of suspected falsified medicines and produce reports and data for the authorities to help improve the reliability of the medicine supply chain.

 We are part of the international community combating falsified medicines. We work in close cooperation with the European medicines verification community and ensure that the needs and perspectives of the Finnish pharmaceutical supply chain are heard. We are a leading actor in both collaboration and system development.



PATIENT

SAFETY

COLLABORATION

LEADERSHIE

Leadership

• We leverage the competitive advantage of the secure Finnish pharmaceutical supply chain. Our medicines verification system is exceptionally well implemented, partly thanks to the simplicity of Finland's distribution model. As a result, our system — and the patient safety it delivers — is highly credible. We are a visible and influential voice in discussions concerning the operating environment of the medicines verification system. We actively highlight the benefits of the system and the threats posed by falsified medicines.

 We communicate proactively with supply chain stakeholders, authorities, and citizens alike.

 We are committed to operational excellence, ensuring that the financial investments made in the medicines verification system deliver the best possible outcomes and tangible benefits for both supply chain stakeholders and medicine users.



PATIENT

SAFETY

LEADERSHIP

COLLABORATION